Terrence J. Bradley

Terrence J. Bradley

Hematology
1475 Northwest 12th Avenue
Miami, FL 33136

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

Dasatinib Exposure and Risk of CMV Reactivation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Dasatinib Exposure and Risk of CMV Reactivation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Journal: American journal of hematology
Published: March 09, 2026

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.

Journal: Future oncology (London, England)
Published: March 07, 2026

Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy.

Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy.

Journal: Haematologica
Published: December 12, 2025

Factors affecting treatment decisions for lower-risk myelodysplastic syndromes across practice settings.

Factors affecting treatment decisions for lower-risk myelodysplastic syndromes across practice settings.

Journal: Leukemia & lymphoma
Published: August 25, 2025

Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia.

Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia.

Journal: EJHaem
Published: April 02, 2025

Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy.

Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy.

Journal: Blood advances
Published: December 24, 2024

Response and outcomes of patients with IDH1/2- mutated accelerated/blast-phase myeloproliferative neoplasms.

Response and outcomes of patients with IDH1/2- mutated accelerated/blast-phase myeloproliferative neoplasms.

Journal: Blood neoplasia
Published: December 19, 2024

Functional cure with single agent olutasidenib in relapsed IDH1/NPM1 co-mutated AML.

Functional cure with single agent olutasidenib in relapsed IDH1/NPM1 co-mutated AML.

Journal: NPJ precision oncology
Published: October 29, 2024

Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era.

Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era.

Journal: Blood advances
Published: February 06, 2024

Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia.

Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia.

Journal: Blood neoplasia
Published: November 13, 2023

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 13, 2023

Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.

Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 08, 2023
Showing 1-12 of 25

Last Updated: 09/26/2026